Eculizumab
Eculizumab
Definition
A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05)
Also known as ABP 959, ABP-959, ABP959, Alexion, BCD 148, BCD-148, BCD148, ECULIZUMAB, Eculizumab Biosimilar ABP 959, Eculizumab Biosimilar BCD-148, Eculizumab Biosimilar SB12, Eculizumab-beke, Eculizumab-epys, Elizaria, h5G1.1, Immunoglobulin, Anti-(Human Complement C5 Alpha-Chain) (Human-Mouse Monoclonal 5G1.1 Heavy Chain), Disulfide with Human-Mouse Monoclonal 5G.1.1 Light Chain, Dimer, Monoclonal antibody 5G1.1, SB 12, SB-12, SB12, Soliris — per NCIT
Also identified as
- ATC L04AJ01 per RXNORM
- NCIT NCIT:C48386 per NCIT
- SCTID 426801002 per RXNORM
- SCTID 427429004 per RXNORM
- UNII A3ULP0F556 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Atypical hemolytic-uremic syndrome | may treat | MEDRT · Public domain (U.S. Government work) |
| Myasthenia gravis | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Musculature | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Musculoskeletal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Nervous system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Peripheral nervous system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
4 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.